Preclinical News and Research

RSS

WIRB-Copernicus Group acquires Alliance Biosciences

WIRB-Copernicus Group, the world's largest provider of regulatory and ethical review services for clinical research, announced today that it has acquired Alliance Biosciences. Formerly a division of Richmond, VA-based Alliance Engineering, Alliance Biosciences was the leading biosafety and biosecurity consulting firm in the United States.

24 Jul 2014

Co-targeting strategies suggested for EGFR-TKI resistance in NSCLC

Researchers have identified additional resistance mechanisms that could be targeted to improve the efficacy of irreversible epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small-cell lung cancer harbouring both EGFR and T790M mutations.

23 Jul 2014

Cedars-Sinai investigators developing novel treatment for locally advanced pancreatic cancer

Investigators at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute are developing a novel, multistep investigational treatment for one of the most complex and difficult-to-treat forms of the disease, locally advanced pancreatic cancer.

23 Jul 2014

Advaxis, MedImmune team up for immuno-oncology clinical trial

Advaxis, Inc., a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca.

23 Jul 2014

Glide Pharma announces successful completion of pre-clinical proof-of-concept study with novel solid formulation of octreotide acetate

Glide Pharma, the pharmaceutical development and device company focused on solid dose formulations of therapeutics and vaccines, today announced that its novel solid formulation of octreotide acetate achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Sandostatin®).

22 Jul 2014

Xstrahl, MacroMedics sign contract to distribute state-of-the-art fixation devices in the USA

MacroMedics BV the innovation leader in patient fixation devices has signed a distribution contract with Xstrahl in the USA. Xstrahl have been successfully distributing MacroMedics in the UK for 3 years. This partnership has allowed radiotherapy centers across the UK to gain access to the innovative and versatile systems. Now Xstrahl will be offering these unique products to US hospitals.

From Xstrahl 22 Jul 2014

A personalized approach for patients with ccRCC-related mutations

In an analysis of small molecules called metabolites used by the body to make fuel in normal and cancerous cells in human kidney tissue, a research team from the Perelman School of Medicine at the University of Pennsylvania identified an enzyme key to applying the brakes on tumor growth.

21 Jul 2014

Researchers identify group of cells in brain that plays important role in Down syndrome

Researchers from UC Davis School of Medicine and Shriners Hospitals for Children - Northern California have identified a group of cells in the brain that they say plays an important role in the abnormal neuron development in Down syndrome.

21 Jul 2014

Doctor maps path of discovery for developing potential anticancer agent

The journal Cancer Cell today published research led by Dr. Tak Mak mapping the path of discovery to developing a potential anticancer agent.

18 Jul 2014

Lilly, Immunocore enter into co-discovery and co-development collaboration to develop cancer therapies

Eli Lilly and Company and Immunocore Limited today announced they have entered into a co-discovery and co-development collaboration to research and potentially develop novel T cell-based cancer therapies.

16 Jul 2014

Chemoprevention and colon cancer: an interview with Dr. John Letterio, Case Western Reserve University School of Medicine

The basic idea of cancer chemoprevention is to arrest or reverse the progression of premalignant cells towards full malignancy, using physiological mechanisms that do not kill healthy cells.

16 Jul 2014

Pfizer to in-license Absorption Systems' BCRP-MDCK cells

Absorption Systems, a leader in novel test systems for drug transporters, announces a license agreement with Pfizer Inc., in which Pfizer will in-license Absorption Systems' BCRP-MDCK cells. This cell line is stably transfected with the human ABCG2 gene, which codes for a protein known as BCRP (breast cancer resistance protein).

15 Jul 2014

MIIR partners with international biosciences to develop potential anti-cancer drugs

The Marshall Institute for Interdisciplinary Research (MIIR) and the Marshall University Joan C. Edwards School of Medicine today announced they will be partnering with an international biosciences company to develop potential anti-cancer drugs.

11 Jul 2014

Baxter International acquires drug candidate developed to treat sickle cell disease

A drug candidate developed by researchers at the NIH's National Center for Advancing Translational Sciences and its collaborators to treat sickle cell disease has been acquired by Baxter International's BioScience business.

11 Jul 2014

New approach for developing personalized gene therapies to treat retinitis pigmentosa

Columbia University Medical Center researchers have created a way to develop personalized gene therapies for patients with retinitis pigmentosa (RP), a leading cause of vision loss.

11 Jul 2014

HD Biosciences and MIIR partner to co-develop potential anti-cancer drugs

HD Biosciences Co., Ltd. (HDB), the Marshall Institute for Interdisciplinary Research (MIIR) and the Marshall University Joan C. Edwards School of Medicine announced the new partnership to co-develop potential anti-cancer drugs.

10 Jul 2014

Exeter scientists find health benefits in rotten egg gas

It may smell of flatulence and have a reputation for being highly toxic, but when used in the right tiny dosage, hydrogen sulfide is now being being found to offer potential health benefits in a range of issues, from diabetes to stroke, heart attacks and dementia. A new compound (AP39), designed and made at the University of Exeter, could hold the key to future therapies, by targeting delivery of very small amounts of the substance to the right (or key) places inside cells.

10 Jul 2014

New mechanism of chemotherapy resistance in triple-negative inflammatory breast cancer

Researchers at Roswell Park Cancer Institute (RPCI) have identified a mechanism of breast cancer cells that leads to chemotherapy resistance in inflammatory breast cancer.

8 Jul 2014

Maternal inflammatory marker linked to children’s schizophrenia risk

The children of women who have elevated levels of the inflammatory marker C-reactive protein during pregnancy have an increased risk of developing schizophrenia, research suggests.

3 Jul 2014

MedImmune initiates MEDI8897 phase I clinical studies for treatment of RSV infections

AIMM Therapeutics, a leading human therapeutic antibody company, today announced that its partner MedImmune, LLC, the global biologics unit of AstraZeneca, has initiated phase I clinical studies with MEDI8897, a best-in-class antibody for the treatment of respiratory syncytial virus (RSV) infections in young, at risk children.

2 Jul 2014

Preclinical News and Research

WIRB-Copernicus Group acquires Alliance Biosciences

Co-targeting strategies suggested for EGFR-TKI resistance in NSCLC

Cedars-Sinai investigators developing novel treatment for locally advanced pancreatic cancer

Advaxis, MedImmune team up for immuno-oncology clinical trial

Glide Pharma announces successful completion of pre-clinical proof-of-concept study with novel solid formulation of octreotide acetate

Xstrahl, MacroMedics sign contract to distribute state-of-the-art fixation devices in the USA

A personalized approach for patients with ccRCC-related mutations

Researchers identify group of cells in brain that plays important role in Down syndrome

Doctor maps path of discovery for developing potential anticancer agent

Lilly, Immunocore enter into co-discovery and co-development collaboration to develop cancer therapies

Chemoprevention and colon cancer: an interview with Dr. John Letterio, Case Western Reserve University School of Medicine

Pfizer to in-license Absorption Systems' BCRP-MDCK cells

MIIR partners with international biosciences to develop potential anti-cancer drugs

Baxter International acquires drug candidate developed to treat sickle cell disease

New approach for developing personalized gene therapies to treat retinitis pigmentosa

HD Biosciences and MIIR partner to co-develop potential anti-cancer drugs

Exeter scientists find health benefits in rotten egg gas

New mechanism of chemotherapy resistance in triple-negative inflammatory breast cancer

Maternal inflammatory marker linked to children’s schizophrenia risk

MedImmune initiates MEDI8897 phase I clinical studies for treatment of RSV infections

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics